Neogen Financial Ratios
NASDAQ: NEOGHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neogen ratio analysis
Neogen earned a net margin of -0.9% in FY 2026, up from -122.1% a year earlier. Gross margin was 46.9% compared with a median of 46.9% over the prior 9 years. Return on equity reached -0.4%, meaning Neogen generated -0.00 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.38 versus 0.43 the year before, and the current ratio was 3.82. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Neogen financial ratios (annual)
| Ratio | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | — | 58.02 | 79.37 | 63.59 | 49.43 | 31.26 | 28.71 |
| Price / sales | 2.24 | 1.42 | 3.08 | 4.25 | 5.33 | 10.28 | 8.95 | 7.06 | 4.88 | 3.48 |
| Price / book | 0.93 | 0.61 | 0.91 | 1.12 | 3.17 | 5.73 | 5.16 | 4.58 | 3.47 | 2.65 |
| Gross margin | 46.9% | 47.1% | 50.2% | 49.4% | 46.1% | 45.9% | 46.9% | 46.3% | 46.8% | 47.1% |
| Operating margin | -2.5% | -118.6% | 6.3% | 4.6% | 11.1% | 15.8% | 16.1% | 16.4% | 17.6% | 18.1% |
| Net margin | -0.9% | -122.1% | -1.0% | -2.8% | 9.2% | 13.0% | 14.2% | 14.5% | 15.9% | 12.2% |
| Free cash flow margin | 3.7% | -5.2% | -8.2% | -3.0% | 8.3% | 11.6% | 14.8% | 11.9% | 12.1% | 12.8% |
| Return on equity (ROE) | -0.4% | -52.7% | -0.3% | -0.7% | 5.4% | 7.2% | 8.2% | 9.4% | 11.3% | 9.3% |
| Return on assets (ROA) | -0.2% | -31.7% | -0.2% | -0.5% | 4.9% | 6.6% | 7.5% | 8.6% | 10.2% | 8.3% |
| Debt / equity | 0.38 | 0.43 | 0.28 | 0.57 | 0.00 | — | — | — | — | — |
| Current ratio | 3.82 | 3.32 | 3.82 | 4.03 | 8.05 | 11.03 | 11.08 | 11.75 | 9.71 | 8.14 |
| Revenue growth | -2.7% | -3.2% | 12.4% | 56.0% | 12.5% | 12.0% | 1.0% | 4.1% | 11.1% | 11.5% |
| EPS growth | — | — | — | -126.7% | -21.1% | 1.8% | -1.8% | -52.9% | 40.7% | 19.4% |